Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BiOptic's Revenue for the
six
months ended in Dec. 2025 was NT$129.0 Mil. BiOptic's average Accounts Receivable for the
six
months ended in Dec. 2025 was NT$19.2 Mil.
Hence, BiOptic's Receivables Turnover for the
six
months ended in Dec. 2025 was 6.71.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BiOptic Receivables Turnover Related Terms
BiOptic Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BiOptic's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, BiOptic's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BiOptic's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a Receivables Turnover of 6.71 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BiOptic and its competitors. According to the industry distribution chart, BiOptic ranks #203 out of 842 companies in the Biotechnology industry, placing it in the top 24.1%.
Is BiOptic's Receivables Turnover too high?
BiOptic's current Receivables Turnover is 6.71. The Biotechnology industry median Receivables Turnover is 5.27. BiOptic's value of 6.71 is 27.4% above this industry median. Based on the distribution chart, BiOptic ranks #203 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BiOptic has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #203 out of 842 companies for Receivables Turnover. This places BiOptic in the top 24% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. BiOptic's value of 6.71 is 27.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BiOptic's current Receivables Turnover of 6.71 is 27.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BiOptic and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BiOptic's current Receivables Turnover is 6.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.94, compared to a current price of NT$33.30 — trading 25.9% below its estimated fair value. The current Receivables Turnover is 6.71 and 27.4% above the Biotechnology industry median of 5.27. BiOptic's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current Receivables Turnover is 6.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$33.30 is trading 25.9% below its estimated GF Value™ of NT$44.94.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
Receivables Turnover: 6.71
GF Value™: NT$44.94 vs. price of NT$33.30 (25.9% below fair value)
Industry Position: 27.4% above the Biotechnology median (#203 of 842)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
90GF Score
Get the complete analysis for ROCO:6850
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
